CTOs on the Move

Spark Therapeutics

www.sparktx.com

 
At Spark Therapeutics, we don`t follow footsteps. We create the path. We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. Our mission is seemingly impossible to others, but not to us: Challenge the inevitability of genetic disease by discovering, developing and delivering treatments in ways unimaginable – until now. Since our founding, we have been committed to bringing a wide range of expertise to build a fully integrated gene therapy company focused on inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.sparktx.com
  • 3737 Market Street
    Philadelphia, PA USA 19104
  • Phone: 215.220.9300

Executives

Name Title Contact Details
Scott Strahler
Chief Information Officer (CIO) North America Profile
Amy Shillingford
Head of Information Technology Profile
Cynthia Pussinen
Chief Technical Officer Profile

Similar Companies

Wheeler Bio

A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.

Powerpollen

PowerPollen offers a breakthrough, scalable technology to collect, preserve and apply pollen on-demand to help improve the productivity, profitability and sustainability of modern farming practices.

Shionogi USA

Shionogi USA, Inc. is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Guava Technologies

Guava Technologies, Inc. is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.